Novo Nordisk and Lilly, two pharmaceutical giants behind the blockbuster diabetes and obesity drugs Ozempic, Wegovy, Mounjaro, and Zepbound (Ozempic, et al.), currently find themselves embroiled in legal battles with wellness centers, medical spas, and compounding pharmacies. Both companies are taking action to protect their trademarks and intellectual property.  Despite being separate companies, the key trademark-related legal concerns they face have significant overlap.